3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
6
Glioblastoma
4
Central Nervous System Neoplasms
3
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pheochromocytoma
1
Interventions
Docetaxel
6
Radiotherapy
5
Filgrastim
3
Erlotinib Hydrochloride
3
Cetuximab
3
Capecitabine
3
Bevacizumab
3
entrectinib
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Acupuncture Therapy
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
cevimeline
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Immunotherapy
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled